Abstract:Abstract Abstract 4621 Objective: Canonical Wnt signaling controls embryonic development, regulates cell growth, transference and differentiation, it also involves in the self-renewal process of normal tissue and multiplication of stem cell. Recently, the aberrant activation of the Wnt signaling pathway has been implicated in the pathogenesis of human neoplasm including leukemia. LEF1, as a major transcriptional factor of Wnt signaling, plays a pivotal role in lymphoid differentiation as well as in granulopoiesis. High expression of LEF1 has been proposed to be a novel favorable prognostic factor in cytogenetically normal acute myeloid leukemia (AML). In this study, we firstly investigated the expression level of LEF1 mRNA and its clinical significance in Chinese AML. Methods: 87 samples from 81 Chinese AML patients (81 primary untreated samples and 6 samples after induction therapy) and 14 healthy controls were collected in this study. The LEF1 mRNA expressions were measured by real-time PCR with fluorescent dye SYBR Green I, the GAPDH was used as internal control. The relative quantitative value of LEF1 expression was calculated by means of 2 (−ΔCt). We analyzed the results with established AML prognostic factors such as karyotype, gene mutations, fusion proteins, relapse-free survival (RFS) and overall survival (OS). Results: The expression level of LEF1 mRNA in 81 AML patients was significantly higher than 14 normal controls (p <0.001). LEF1 expression level was further analyzed in the subgroups distinguished by clinical characters. According to national comprehension cancer network (NCCN) guideline, we found that LEF1 was dramatically increased in patients with better risk karyotype group (n=18) than those with the intermediate risk karyotype group (n=51) (P=0.031); patients with PML-RARα positive (n=16) and AML1-ETO positive (n=5) have higher LEF1 level compared with those without PML-RARα or AML1-ETO (n=60). Among 70 patients who have received the induction therapy, we discovered that patients with relative higher LEF1 expression were more likely to achieve CR after first induction therapy (p= 0.031; CR: n=44, no CR: n=26); we further analyzed the samples before and after treatment from 6 patients who achieved CR, the results showed that the LEF1 level were dramatically decreased after first induction therapy (p=0.028). We can not find the differences in RFS and OS between low LEF1 expression group and high LEF1 expression group in total patients. However, among the AML patients with intermediate risk cytogenetic, the lower LEF1 expression was associated with worse RFS (median, 15.0 vs 31.7 months, P=0.044) and OS (median, 16.7 vs 33.7 months, P=0.046) compared with the higher LEF1 expression. Conclusion: These results showed the LEF1 expression in AML patients is markedly higher than normal controls, especially in patients with favorable risk karyotype and PML-RARα or AML1-ETO positive. Patients with higher LEF1 expression seems to more likely to achieve CR after induction therapy. Survival analysis revealed that the higher LEF1 expression patients have a significantly prolonged RFS and OS compared to the lower LEF1 expression patients in intermediate risk karyotype group of AML. Our results in Chinese patients verified that LEF1 can be a potential favorable marker in AML patients. Disclosures: No relevant conflicts of interest to declare.

Extracellular matrix protein 1 (ECM1) is a potential biomarker in B cell acute lymphoblastic leukemia

A combined immune and exosome-related risk signature as prognostic biomakers in acute myeloid leukemia

High Expression of TET1 Predicts Poor Survival in Cytogenetically Normal Acute Myeloid Leukemia from Two Cohorts.

ETS-related Gene is a Novel Prognostic Factor in Childhood Acute Lymphoblastic Leukemia.

Overexpression of Lymphoid Enhancer‐binding Factor‐1 (LEF1) is a Novel Favorable Prognostic Factor in Childhood Acute Lymphoblastic Leukemia

Clinical and Genetic Characteristics of IKZF1 Mutation in Chinese Children with B-Cell Acute Lymphoblastic Leukemia.

Extracellular matrix protein 1 (ECM1) is associated with carcinogenesis potential of human bladder cancer.

Clinical Features and Prognostic Implications of Ecotropic Viral Integration Site 1 (EVI1) in Childhood Acute Lymphoblastic Leukemia

Clinical Significance of Complement and Coagulation Cascades Genes for Patients With Acute Lymphoblastic Leukemia

C-Type Lectin-Like Molecule-1 as a Biomarker for Diagnosis and Prognosis in Acute Myeloid Leukemia: A Preliminary Study

The prognostic value of bioinformatics analysis of ECM receptor signaling pathways and LAMB1 identification as a promising prognostic biomarker of lung adenocarcinoma

Low EVI1 Expression at Diagnosis Predicted Poor Outcomes in Pediatric Ph-negative B Cell Precursor Acute Lymphoblastic Leukemia Patients

Molecular characterization and biomarker identification in paediatric B-cell acute lymphoblastic leukaemia

Bioinformatics Analysis Identifies EPAS1 as a Novel Prognostic Marker Correlated with Immune Infiltration in Acute Myeloid Leukemia

Abstract 7651: Evaluating epigenetic markers for naive, memory and overall B cells for disease diagnosis and prognosis in patients with B-CLL

The Expression of LEF1 Gene and Its Clinical Significance in Chinese Patients with Acute Myeloid Leukemia

Long Non-coding RNA RP11-252C15.1 is a Potential Biomarker of Prognosis and Hallmark for Leukemogenesis in Children with B-cell Precursor Acute Lymphoblastic Leukemia

Clinical significance of lymphoid enhancer-binding factor 1 expression in acute myeloid leukemia

The Expression Level of Neuronal Calcium Sensor 1 Can Predict the Prognosis of Cytogenetically Normal AML

Integrative Analysis Constructs an Extracellular Matrix-Associated Gene Signature for the Prediction of Survival and Tumor Immunity in Lung Adenocarcinoma

New and emerging prognostic and predictive genetic biomarkers in B-cell precursor acute lymphoblastic leukemia